CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Prophylactic/Intermediate Dose EnoxaparinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug596 Cognitive Stimulation Wiki 1.00
drug852 Enoxaparin Wiki 0.33

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D019965 Neurocognitive Disorders NIH 1.00
D003704 Dementia NIH 0.50
D060825 Cognitive Dysfunction NIH 0.35

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0000726 Dementia HPO 0.50
HP:0001268 Mental deterioration HPO 0.35

There is one clinical trial.

Clinical Trials


1 Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)

The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than prophylaxis with institutional standard of care with prophylactic to intermediate-doses of UFH or LMWH

NCT04401293 Sars-CoV2 COVID Drug: Enoxaparin Drug: Prophylactic/Intermediate Dose Enoxaparin

Primary Outcomes

Description: Risk of arterial thromboembolic events (including myocardial infarction, stroke, systemic embolism), venous thromboembolism (including symptomatic deep vein thrombosis (DVT) of the upper or lower extremity, asymptomatic proximal DVT of the lower extremity, non-fatal pulmonary embolism (PE)), and all-cause mortality at Day 30 ± 2 days.

Measure: Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Day 30 ± 2 days.

Time: Day 30 ± 2 days

Secondary Outcomes

Description: Risk of major bleeding defined using the International Society of Thrombosis and Haemostasis (ISTH) criteria

Measure: Major bleeding

Time: Day 30 ± 2 days

Description: The composite of arterial thromboembolic events (including myocardial infarction, stroke, systemic embolism), venous thromboembolism (including symptomatic deep vein thrombosis (DVT) of the upper or lower extremity, asymptomatic proximal DVT of the lower extremity, non-fatal pulmonary embolism (PE)), and all-cause mortality at Hospital Day 10 + 4

Measure: Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Hospital Day 10 + 4

Time: Day 10 + 4

Description: Sepsis-induced coagulopathy (SIC) score based on ISTH guidelines. Platelets, K/uL (thousands per microliter) [0-2] INR (International Normalized Ratio) [0-2] D-Dimer Levels, ng/mL [0-3] Fibrinogen, mg/dL [0-1] Calculated (SIC) scores greater or equal to 4 predicted higher mortality rates within 30 days and greater risk of pulmonary embolism.

Measure: Sepsis-induced coagulopathy (SIC) score

Time: Day 30 ± 2 days.

Description: Progression to Acute Respiratory Distress Syndrome (ARDS) based on monitoring of patient conditions.

Measure: Progression to Acute Respiratory Distress Syndrome (ARDS)

Time: Day 30 ± 2 days.

Description: Need for Intubation will be based on monitoring of patient conditions.

Measure: Need for Intubation

Time: Day 30 ± 2 days.

Description: Need for Re-hospitalization will be based on monitoring of patient conditions.

Measure: Re-hospitalization

Time: Day 30 ± 2 days.


No related HPO nodes (Using clinical trials)